What's in Taizhou Mabtech Pharmaceutical Co.,Ltd's pipeline?

Taizhou Mabtech Pharmaceutical Co.,Ltd has 10 drugs in our index: 1 marketed, 0 filed, 3 in Phase 3, 0 in Phase 2, 6 in Phase 1.

Which companies overlap with Taizhou Mabtech Pharmaceutical Co.,Ltd's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/taizhou-mabtech-pharmaceutical-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Taizhou Mabtech Pharmaceutical Co.,Ltd — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Taizhou Mabtech Pharmaceutical Co.,Ltd pipeline: 1 marketed, 0 filed, 3 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 3 Phase 3 0 Phase 2 6 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Target	Area
Xolair	Xolair	marketed	Ig epsilon chain C region	Respiratory
CMAB015	CMAB015	phase 3		Oncology
CMAB007	CMAB007	phase 3		Oncology
CMAB009	CMAB009	phase 3		Oncology

Therapeutic area mix

Oncology · 3
Respiratory · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Taizhou Mabtech Pharmaceutical Co.,Ltd:

Cite this brief

Drug Landscape (2026). Taizhou Mabtech Pharmaceutical Co.,Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/taizhou-mabtech-pharmaceutical-co-ltd. Accessed 2026-05-16.